MARKET

IMNM

IMNM

Immunome Inc
NASDAQ
21.50
-0.64
-2.89%
After Hours: 21.56 +0.06 +0.28% 19:58 02/20 EST
OPEN
21.94
PREV CLOSE
22.14
HIGH
22.16
LOW
21.32
VOLUME
1.08M
TURNOVER
--
52 WEEK HIGH
27.65
52 WEEK LOW
5.15
MARKET CAP
2.37B
P/E (TTM)
-7.2795
1D
5D
1M
3M
1Y
5Y
1D
Immunome: Advancing Best-in-Class Varegacestat and a Data-Driven ADC Pipeline Support Buy Rating and $40 Target
TipRanks · 3d ago
Weekly Report: what happened at IMNM last week (0209-0213)?
Weekly Report · 4d ago
Shopify upgraded, Coinbase downgraded: Wall Street’s top analyst calls
TipRanks · 02/12 14:45
This Sezzle Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Thursday
Benzinga · 02/12 13:41
Immunome Price Target Announced at $40.00/Share by HC Wainwright & Co.
Dow Jones · 02/12 12:08
Immunome Initiated at Buy by HC Wainwright & Co.
Dow Jones · 02/12 12:08
HC Wainwright & Co. Initiates Coverage On Immunome with Buy Rating, Announces Price Target of $40
Benzinga · 02/12 11:58
Immunome: Differentiated Oncology Portfolio and ADC Platform Underpin Buy Rating and $40 Price Target
TipRanks · 02/12 11:15
More
About IMNM
Immunome, Inc. is a clinical-stage targeted oncology company, which is focused on developing first-in-class and targeted therapies designed to improve outcomes for cancer patients. The Company is engaged in advancing an innovative portfolio of therapeutics in the design, development, and commercialization of targeted cancer therapies, including antibody-drug conjugate therapies (ADCs). Its advanced pipeline programs are varegacestat, a gamma secretase inhibitor which is in a Phase III trial for the treatment of desmoid tumors; IM-1021, an ROR1-targeted ADC which is in a Phase I trial, and IM-3050, a FAP-targeted radioligand. The Company's pipeline also includes IM-1617, IM-1335, and IM-1340, all of which are preclinical ADCs pursuing undisclosed targets with expression in multiple solid tumors. IM-1617 is a potential first-in-class ADC that targets an undisclosed receptor that is expressed in a range of solid tumors, including colorectal cancer and ovarian cancers.

Webull offers Immunome Inc stock information, including NASDAQ: IMNM real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IMNM stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading IMNM stock methods without spending real money on the virtual paper trading platform.